In view of continuing COVID-19 related challenges, the ESH “6th Translational Research Conference: Lymphoid Malignancies” will be held as a ..
virtual event. This leading-edge translational research conference will address the rapidly evolving field of lymphoid malignancies, including T- and B-cell lymphomas, and chronic lymphocytic leukaemia (CLL), from molecular pathogenesis to state-of-the-art treatment and future perspectives. A first-class selection of international speakers will guarantee the highest quality of science and a summary of the most recent developments in the biology and therapy of Lymphoid Malignancies. Improved understanding of : – current developments in the field of molecular pathogenesis of indolent and aggressive B-cell lymphoma including CLL – current developments in the field of the molecular pathogenesis of T-cell lymphoma – prognostic and predictive markers and their impact in specific clinical situations – current treatments and future therapeutic perspectives. – B-cell development and lymphomagenesis – Genetics of malignant lymphomas and clonal evolution – Epigenetics in malignant lymphomas – Deregulated proteome and metabolome – Single cell analyses, circulating tumor DNA, MRD – Oncogenic signaling pathways – Utilizing oncogenic signaling therapeutically – Immunologic approaches in the treatment of lymphomas.